Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
May 6, 2021

Ironwood Pharmaceuticals Reports First Quarter 2021 Results

April 22, 2021

Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call

February 19, 2021

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

February 17, 2021

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance

February 8, 2021

Ironwood Pharmaceuticals Announces CEO Transition

February 3, 2021

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call

January 5, 2021

Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 3, 2020

Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors

November 6, 2020

Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference

November 5, 2020

Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance

November 5, 2020

Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors

October 22, 2020

Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call

September 29, 2020

Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

September 2, 2020

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 6, 2020

Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million

Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.